ストックスクリーナーアプリを入手
1.14
6.56%
-0.08
プレマーケット:
1.15
0.01
+0.88%
前日終値:
$1.22
開ける：
$1.21
24時間の取引高:
984.17K
Relative Volume:
1.77
時価総額：
$95.43M
収益：
-
当期純損益:
$-21.65M
株価収益率:
-3.4327
EPS:
-0.3321
ネットキャッシュフロー:
$-15.84M
1週間 パフォーマンス:
+0.88%
1か月 パフォーマンス:
-4.20%
6か月 パフォーマンス:
-6.56%
1年 パフォーマンス:
-41.54%
1日の値動き範囲:
$1.10
$1.22
1週間の範囲:
$1.10
$1.4199
52週間の値動き範囲:
$0.7709
$2.63
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
CRDL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.14 | 108.27M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
155.67 | 68.30B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.20 | 47.37B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.74 | 43.29B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.56 | 20.49B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
313.22 | 14.16B | 2.99B | 1.21B | 1.13B | 25.06 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-26 | 開始されました | ROTH MKM | Buy |
| 2024-04-22 | 開始されました | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc (CRDL) 最新ニュース
Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses - MSN
Cardiol rises on database lockup for acute myocarditis therapy trial - MSN
Cardiol Therapeutics Inc. shares fall 1.64% after-hours as stock futures decline ahead of Trump's Ukraine meeting. - AInvest
A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics - thedeepdive.ca
Why is Cardiol Therapeutics Inc. stock going downTrade Exit Report & Expert Approved Momentum Ideas - thegnnews.com
Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cardiol Therapeutics shares rise 1.49% premarket after BioCardia and CART-Tech announce exclusive development and commercialization agreement for Heart3D Fusion Imaging. - AInvest
Cardiol Therapeutics: Promising Developments in Cardiac Disease Treatment with CardiolRx - TipRanks
The Significance of Moving Averages in Cardiol Therapeutics Inc Inc. (CRDL) Price Performance - investchronicle.com
Healthcare Analysts Bullish on SI-Bone, Delcath Systems, and Cardiol Therapeutics - AInvest
Chart based analysis of Cardiol Therapeutics Inc. trendsJuly 2025 Update & Free Real-Time Market Sentiment Alerts - Newser
What technical models suggest about Cardiol Therapeutics Inc.’s comebackPortfolio Risk Summary & Entry and Exit Point Strategies - Newser
How to integrate Cardiol Therapeutics Inc. into portfolio analysis toolsJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
Relief Rally in Cardiol Therapeutics Inc. Stock — Can It Hold [Insider Selling]Low Drawdown Trading Strategies - 선데이타임즈
Will Cardiol Therapeutics Inc. stock go up soon [2025 Trading Volume Trends]Free Community Trade Idea Sharing Platform - Newser
Analyzing Cardiol Therapeutics Inc. with multi timeframe chartsAI-Based Stock Behavior Forecast Engine - Newser
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH) - TradingView
Analyzing drawdowns of Cardiol Therapeutics Inc. with statistical toolsWeekly Growth Portfolio Performance Summary - Newser
Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada - streetwisereports.com
Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment - streetwisereports.com
Biotech Announces Topline Results From Cardiovascular Drug Trial - streetwisereports.com
Cardiol Therapeutics to Participate in Fireside Chat at Canaccor - GuruFocus
Cardiol Therapeutics to Present at Canaccord Genuity Conference - TipRanks
Fluor Acknowledges Court Decision on Santos’ Gladstone LNG Project - The Globe and Mail
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference - Newsfile
Cardiol Therapeutics Reveals Latest Heart Disease Treatment Progress at Major Growth Conference - Stock Titan
Moving Average Trends for Cardiol Therapeutics Inc. Stock: What They IndicateEntry Confirmation Based on Volatility Analysis - Newser
Canadian Pharma Finds Promising Cardiovascular Breakthrough - streetwisereports.com
Watch for Trend Continuation in Cardiol Therapeutics Inc. Next WeekPortfolio Diversification Stock Ideas From Experts - beatles.ru
Cardiol Therapeutics (CRDL) Expected to Announce Earnings on Monday - Defense World
(CRDL) Risk-Controlled Trading Report (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics CRDL 2025Q2 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Cardiol Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Is Cardiol Therapeutics a buy? - Cantech Letter
Cardiol Therapeutics’ stock down 20% on Phase II CardiolRx failure - Yahoo Finance
Cardiol Therapeutics Announces US Listing - thedeepdive.ca
Cardiol Therapeutics shares rise 7.48% premarket after positive ARCHER trial results for CardiolRx™. - AInvest
Cardiol falls after mid-stage data for heart disease treatment - MSN
Roth bullish on Cardiol, says trial results enough to attract larger partner - TipRanks
Quantum Biopharma Ltd. shares rise 1.19% after-hours following Cardiol Therapeutics' positive ARCHER trial results. - AInvest
Cardiol data readout positive and not priced in, says H.C. Wainwright - TipRanks
Cardiol Therapeutics’ Cannabidiol Formulation Reduced Inflammation—Phase II Topline Data Ignites the Race to Treat Acute Myocarditis - InvestorNews
Cardiol ARCHER study not statistically significant, says Canaccord - TipRanks
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Barchart.com
Cardiol Therapeutics Reports Promising Phase II Trial Results for CardiolRx™ in Acute Myocarditis - TipRanks
Cardiol falls after mid-stage data for heart disease drug - Seeking Alpha
Cardiol Therapeutics Announces Topline Results from the Phase II - GuruFocus
(CRDL) Trading Report (CRDL:CA) - news.stocktradersdaily.com
Optimistic Buy Rating for Cardiol Therapeutics Amid Promising Clinical Trial Results and Strategic Advancements - TipRanks
Cardiol Therapeutics shares rise 2.73% intraday after Windtree announces Istaroxime Phase 2 interim analysis. - AInvest
Cardiol Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsWatchlist for Smart Swing Trading Updated - beatles.ru
Cardiol Therapeutics Inc (CRDL) 財務データ
収益
当期純利益
現金流量
EPS
2.61%
1.02%
大文字化:
|
ボリューム (24 時間):